<DOC>
	<DOCNO>NCT01141959</DOCNO>
	<brief_summary>The investigator interested identifying patient-specific factor relate donor chimerism patient receive nonmyeloablative hematopoietic stem cell transplant haploidentical donor . We look patient ' body break immediately respond cyclophosphamide , fludarabine mycophenolate mofetil .</brief_summary>
	<brief_title>Blood Samples Identify Biomarkers Haploidentical Graft Recipients</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Scheduled receive nonmyeloablative conditioning include fludarabine Scheduled receive haploidentical graft Scheduled receive postgrafting immunosuppression include oral mycophenolate mofetil ( MMF ) entericcoated mycophenolic acid Age &gt; 18 year time enrollment Diagnosed immunodeficiency disorder , include HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>hematopoietic stem cell transplantation</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>fludarabine</keyword>
	<keyword>mycophenolate mofetil</keyword>
	<keyword>mycophenolic acid</keyword>
	<keyword>biomarkers</keyword>
</DOC>